Contributors
-
TwentyTwentyTweets
-
Join 7,195 other subscribers
-
Recent Posts
Pages
Category Archives: Genetics
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011
As 2011 draws to a close now is a good time to reflect on the period since the last UK General Election in 2010. We must consider what we have done right, what we have done wrong and what remains … Continue reading
Posted in Business, David Cameron, Department of Health, Drugs, Election, Genetics, Health Bill, Health Team, Hospitals, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, David Cameron, Department of Health, Drugs, genetics, government, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot – The UK Needs More Biotechnology Companies
The success of US biotechnology companies contrasts sharply with the disappointment in other countries. British companies valued by stock markets at more than about US $ 4 billion go in the FTSE 100 index. There are no biotechnology companies big … Continue reading
Posted in Business, Drugs, Emerging technologies, Finance, Genetics, Pharma, Policy, Research, Technology
Tagged 2020health, Amgen, biotechnology, biotechnology company, block-buster, blockbuster, BTG, drug pricing, Genentech, genetics, medicine, Nobel Prize, patent box, pharmaceutical, pricing, R&D, R&D tax credit, Research, value-based, value-based pricing
1 Comment
Ludicrous advice on genetic tests from the government advisory body
The recommendation from the Human Genetics Commission (HGC) that teenagers should have genetic tests before becoming sexually active is ludicrous (reported in Telegraph). Not for the first time the HGC are making recommendations that could be called at best inadequate. … Continue reading
Don’t buy those pointless gene tests
The weekend’s coverage of the ‘genes for longevity’ is yet another in a long line of genetic studies that tell us nothing that we didn’t already know. However it sows another seed of unrealistic expectation in the mind of the … Continue reading
2020health's Blog 
You must be logged in to post a comment.